Controversies on Lung Cancer: Pros and Cons (Section Chairs: Suresh Senan, Helmut H. Popper)
Rebuttal from Prof. Rodrigues
Abstract
I congratulate Drs. Rabatic and Kong on their excellent review of the merits and clinical trial information supporting the use of concurrent chemoradiation for stage III locally advanced non-small cell lung cancer. As they rightly point out, if the goal is the improvement in survival then, on average, the best course of action given the current understanding of this disease entity is the application of concurrent chemoradiation for unresectable patient populations.
